Clinical stage drug re-purposing company specializing on investigating areas of inflammatory bowel disease (IRD), nonalcoholic steatohepatitis (NASH) and chronic kidney disease (CKD) Algernon Pharmaceuticals Inc. (CSE: CSE) (OTCMKTS: AGNPF) says that it has established six hours as the optimum peak stimulation period for DMT in a neuron outgrowth study it conducted.
The pre-clinical in vitro study was carried out by Charles River Laboratories and Algernon confirmed that the increased growth was achieved with a sub-hallucinogenic dose. The data was extracted from the second stage of the vitro experiment designed to focus on the time of infusion need to get maximal cortical neuron outgrowth.
According to the data, a 40% increase in growth was observed in the group treated for 6 hours with 30 nM DMT subject to statistical significance when compared to control. The study results from the six hour period showed more superiority compared to other treatment time periods and doses.
“This is Algernon’s second preclinical study confirming that DMT stimulates brain cell growth at sub-psychedelic doses. In addition, the data is showing that a maximum effect is seen at 6 hours exposure which would translate well for clinical use. We look forward to moving the research program on to a Phase 1 study,” said the company’s CEO, Christopher J. Moreau.
